司美格鲁肽在美降价30%，外媒称患者负担能力是“持续的挑战”

Group 1 - Novo Nordisk has initiated a price reduction for its weight loss drugs Wegovy and Ozempic in the U.S., lowering the out-of-pocket price to $349 per month from $499, a 30% decrease [1] - A limited-time offer allows U.S. patients to pay $199 per dose for the first two months of treatment until March 31, 2026 [1] - The company anticipates that approximately 40 million Americans will gain access to their medications through expanded coverage under Medicaid and Medicare [1] Group 2 - The popularity of obesity treatment drugs, such as Zepbound and Wegovy, has been increasing, with GLP-1 receptor agonists helping individuals lose between 15% to 22% of their body weight, and in some cases, up to 50 pounds or more [1] - Affordability remains a significant challenge for patients, with a recent KFF survey indicating that about half of those using these treatments find it difficult to pay for them [3] - Research from Vanderbilt University Medical Center suggests that when drug costs exceed $100 per month, individuals struggle to afford them [3]